Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature

Table 1 Dynamic changes in target pulmonary lesion measurements and clinical response evaluation over the treatment period

Timepoint (date)	Lesion 1 (right lobe) (mm)	Lesion 2 (right lobe) (mm)	Sum of diameters (mm)	% change from baseline	Response evaluation
Baseline (February 2022)	15.0	35.5	50.5	0	-
Week 6 (April 2022)	14.2	33.0	47.2	-6.50	SD
Week 17 (June 2022)	13.5	32.0	45.5	-9.90	SD
Week 41 (December 2022)	13.0	29.4	42.4	-16.00	SD
Week 56 (March 2023)	12.4	27.2	39.6	-21.60	SD
Week 82 (September 2023)	11.0	25.5	36.5	-27.70	SD
Week 112 (April 2024)	10.2	22.6	32.8	-35.00	PR
Week 138 (October 2024)	9.1	19.9	29.0	-42.60	PR
Week 164 (April 2025)	8.0	17.6	25.6	-49.30	PR

The percentage change from baseline was calculated based on the sum of diameters for the target lesions. Tumor response was evaluated according to the response evaluation criteria in Solid Tumors version 1.1, where a size reduction of at least thirty percent indicates a partial response. SD: Stable disease; PR: Partial response.